Efficacy of once or twice weekly administration of epoetin κ in patients receiving hemodialysis: A retrospective study

Experimental and Therapeutic Medicine

Volumn 7, Issue 1, 2013, Pages 27-30

  Ohta, Shoichiro ^a   Yasuno, Nobuhiro ^a   Inomoto, Yuki ^a   Matsuda, Kaori ^a   Nakagawa, Yoshihiko ^b   Sasagawa, Isoji ^c   Tanaka, Masahiko ^a  

^a Kan Etsu Hospital   (Japan)

^b Minamicho Clinic   (Japan)

^c Yamagata Tokushukai Hospital   (Japan)

Author keywords

Biosimilar; Epoetin ; Epoetin ; Hemodialysis; Renal failure

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; ERYTHROCYTE COUNT; FEMALE; HEMATOCRIT; HEMODIALYSIS; HUMAN; MALE; PHARMACEUTICAL EQUIVALENCE; RETROSPECTIVE STUDY;

EID: 84887950120     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1384     Document Type: Article

References (15)

1. Pisoni RL, Bragg-Gresham JL, Young EW, etal: Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44: 94-111, 2004.
2. Hirai T, Sugiya N, Nakashima A, Takasugi N and Yorioka N: Switching from epoetin alpha to darbepoietin alpha in Japanese hemodialysis patients: dose conversion ratio. Nephron Clin Pract111: c81-c86, 2009.
3. Okano M, Sato M, Kaneko E and Kageyama S: Doping control of biosimilar epoetin kappa and other recombinant erythropoietins after intravenous application. Drug Test Analysis 3: 798-805, 2011.
4. Brinks V, Hawe A, Basmeleh MA, etal: Quality of original and biosimilar epoetin products. Pharm Res 28: 386-393, 2011.
5. Haag-Weber M, Vetter A and Thyroff-Friesinger U; INJ-Study Group: Therapeutic equivalence, lomg-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin Nephrol 72: 380-390, 2009.
6. European Medicines Agency (EMEA). Committee for Medicinal Products for Human Use (CHMP): Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues-guidance on similar medicinal products containing recombinant erythropoietins. EMEA/CHMP/945626/2005 Corr. 2006.
7. Park SS, Park J, Ko J etal: Biochemical assessment of erythropoietin products from Asia versus US Epoetin alfa manufactured by Amgen. J Pharm Sci 98: 1688-1699, 2009.
8. Jelkmann W: Biosimilar epoetins and other 'follow-on' biologics: update on the European experiences. Am J Hematol85: 771-780, 2010.
9. KDOQI: KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 50: 471-530, 2007.
10. Ebben JP, Glibertson DT, Foley RN and Collins AJ: Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Nephrol 1: 1205-1210, 2006.
11. Schellekens H: How similar do 'biosimilars' need to be? Nat Biotechnol 22: 1357-1359, 2004.
12. Singh AK, Szczech L, Tang KL, etal: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006.
13. Kissei Pharmaceutical Co.: Interview Form, Epoetin-Alpha Bs injection: 2010.
14. Besarab A, Bolton WK, Browne JK, etal: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl JMed 339: 584-590, 1998.
15. Fishbane S and Berns JS: Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 68: 1337-1343, 2005.